 Humanigen Inc NASDAQ: HGEN and Chime Biologics, contract development and manufacturing organization CDMO, have entered into a manufacturing services agreement to produce Humanigens lenzilumab bulk drug substance and drug product for commercial sale. It will follow the receipt of the requisite regulatory authorizations or approvals in regions outside of the U.S., including Europe, the U.K., India, and Brazil. 